The duration of infectiousness of individuals infected with SARS-CoV-2.


Journal

The Journal of infection
ISSN: 1532-2742
Titre abrégé: J Infect
Pays: England
ID NLM: 7908424

Informations de publication

Date de publication:
12 2020
Historique:
received: 28 09 2020
accepted: 07 10 2020
pubmed: 14 10 2020
medline: 8 1 2021
entrez: 13 10 2020
Statut: ppublish

Résumé

To summarise the evidence on the duration of infectiousness of individuals in whom SARS-CoV-2 ribonucleic acid is detected. A rapid review was undertaken in PubMed, Europe PubMed Central and EMBASE from 1 January 2020 to 26 August 2020. We identified 15 relevant studies, including 13 virus culture and 2 contact tracing studies. For 5 virus culture studies, the last day on which SARS-CoV-2 was isolated occurred within 10 days of symptom onset. For another 5 studies, SARS-CoV-2 was isolated beyond day 10 for approximately 3% of included patients. The remaining 3 virus culture studies included patients with severe or critical disease; SARS-CoV-2 was isolated up to day 32 in one study. Two studies identified immunocompromised patients from whom SARS-CoV-2 was isolated for up to 20 days. Both contact tracing studies, when close contacts were first exposed greater than 5 days after symptom onset in the index case, found no evidence of laboratory-confirmed onward transmission of SARS-CoV-2. COVID-19 patients with mild-to-moderate illness are highly unlikely to be infectious beyond 10 days of symptoms. However, evidence from a limited number of studies indicates that patients with severe-to-critical illness or who are immunocompromised, may shed infectious virus for longer.

Identifiants

pubmed: 33049331
pii: S0163-4453(20)30651-4
doi: 10.1016/j.jinf.2020.10.009
pmc: PMC7547320
pii:
doi:

Substances chimiques

RNA, Viral 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

847-856

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2020. Published by Elsevier Ltd.

Auteurs

Kieran A Walsh (KA)

Health Information and Quality Authority, Smithfield, Dublin 7, Ireland. Electronic address: kiwalsh@hiqa.ie.

Susan Spillane (S)

Health Information and Quality Authority, Smithfield, Dublin 7, Ireland.

Laura Comber (L)

Health Information and Quality Authority, Smithfield, Dublin 7, Ireland.

Karen Cardwell (K)

Health Information and Quality Authority, Smithfield, Dublin 7, Ireland; Health Research Board Centre for Primary Care Research, Department of General Practice, Royal College of Surgeons in Ireland, 123 St. Stephens Green, Dublin 2, Ireland.

Patricia Harrington (P)

Health Information and Quality Authority, Smithfield, Dublin 7, Ireland.

Jeff Connell (J)

National Virus Reference Laboratory, University College Dublin, Belfield, Dublin 4, Ireland.

Conor Teljeur (C)

Health Information and Quality Authority, Smithfield, Dublin 7, Ireland.

Natasha Broderick (N)

Health Information and Quality Authority, Smithfield, Dublin 7, Ireland.

Cillian F de Gascun (CF)

National Virus Reference Laboratory, University College Dublin, Belfield, Dublin 4, Ireland.

Susan M Smith (SM)

Health Research Board Centre for Primary Care Research, Department of General Practice, Royal College of Surgeons in Ireland, 123 St. Stephens Green, Dublin 2, Ireland.

Máirín Ryan (M)

Health Information and Quality Authority, Smithfield, Dublin 7, Ireland; Department of Pharmacology & Therapeutics, Trinity College Dublin, Trinity Health Sciences, James Street, Dublin 8, Ireland.

Michelle O'Neill (M)

Health Information and Quality Authority, Smithfield, Dublin 7, Ireland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH